Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | PPIA | P62937 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954898 | 0.86 | TRIM24 (0.46) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20805744 | 0.83 | KMT2A (0.42) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9000485 | 0.81 | KMT2A (0.40) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31048761 | 0.81 | CA1 (0.44) | KMT2AMEN1NPC1RAB9AHTT | |
| SCHEMBL21847253 | 0.79 | KMT2A (0.46) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL13170017 | 0.79 | RAB9A (0.54) | KMT2AMEN1S100A4NPC1RAB9A | |
| SCHEMBL5629538 | 0.77 | RAB9A (0.65) | KMT2ACYP1A2CYP2C9CYP2C19NPC1 | |
| SCHEMBL31076256 | 0.77 | MEN1 (0.60) | KMT2AMEN1CYP2C19S100A4NPC1 | |
| SCHEMBL4449131 | 0.77 | NPC1 (0.56) | KMT2AMEN1NPC1RAB9AATM | |
| SCHEMBL30421156 | 0.77 | RAB9A (0.65) | KMT2ACYP1A2CYP2C9CYP2C19NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3368525-B1 | CGRP RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LTD (GB) | 2019-03-13 | — | — | EP | disclosed |
| EP-1725565-B1 | FUSED HETEROTRICYCLIC COMPOUNDS AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE 3 | BRISTOL MYERS SQUIBB CO (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378426-B2 | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1725565-A2 | FUSED HETEROTRICYCLIC COMPOUNDS AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE 3 | Bristol-Myers Squibb Company (US) | 2006-11-29 | — | — | EP | disclosed |
| EP-0938476-B1 | PROCESS FOR SUBSTITUTED PYRIDINES | PFIZER (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2005084295-A2 | FUSED HETEROTRICYCLIC COMPOUNDS AS INHIBITORS OF 17B-HYDROXYSTEROID DEHYDROGENASE 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-15 | — | — | WO | disclosed |
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-09-01 | — | — | US | disclosed |
| US-6291489-B1 | USEFUL IN THE SYNTHESIS OF CERTAIN .BETA.-ADRENERGIC RECEPTOR AGONISTS | PFIZER INC. | 2001-09-18 | — | — | US | disclosed |
| US-6001856-A | β-adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1999-12-14 | — | — | US | disclosed |
| CN-1237160-A | Process for preparing substituted pyridines | PFIZER (US) | 1999-12-01 | — | — | CN | disclosed |
| EP-0938476-A1 | PROCESS FOR SUBSTITUTED PYRIDINES | PFIZER INC. (US) | 1999-09-01 | — | — | EP | disclosed |
| EP-0887079-A1 | Beta-Adrenergic agonists to reduce a wasting condition | PFIZER INC. (US) | 1998-12-30 | — | — | EP | disclosed |
| WO-1998021184-A1 | PROCESS FOR SUBSTITUTED PYRIDINES | PFIZER INC. (US) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192310-A1 | Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B1, HSD17B2 | KMT2A 3253/4885MEN1 855/4885CYP1A2 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.